Description

This vial contains Reta , a novel “triple agonist” peptide that targets GLP-1, GIP, and Glucagon receptors. This peptide is frequently utilized in research settings to investigate complex metabolic regulation, hepatosteatosis (fatty liver), and energy homeostasis.

Chemical Profile

This product is a high-purity (>99%), lyophilized (freeze-dried) powder requiring reconstitution. It is intended for laboratory handling and experimental analysis only.

• Component: Reta (GGG Tri-Agonist)

• Total Quantity: [5mg or 10mg]

• Purity: >99% (Determined by HPLC)

Quality Assurance

• HPLC Analysis: Validated >99% purity.

• Mass Spectrometry: Confirmed molecular weight and structure.

• Toxicity: Not tested for human safety.

Research Context (Literature Review)

Note: The following is for educational purposes regarding the chemical properties of these peptides and does not constitute a medical claim.

Retatrutide represents the next generation of metabolic research compounds. Unlike single or dual agonists, it activates three receptors: the GLP-1 receptor (insulin secretion), the GIP receptor (lipid metabolism), and the GCGR (Glucagon) receptor (energy expenditure).

In pre-clinical models, the inclusion of glucagon receptor agonism has been observed to increase resting energy expenditure and improve liver fat markers. Research focuses on how this triple-mechanism can profoundly alter metabolic parameters and body composition in obese rodent models.

Technical Specifications